5AM Ventures News and Activities

View the org chart displaying its 24 main executives

Most searched biographies at 5AM Ventures

• Andrew Schwab, Founder and Co-Managing Partner
• Kush Parmar, Co-Managing Partner
• Scott Rocklage, Founding Partner

Popular executive movements at 5AM Ventures

• Lauren Daniel, who was Chief Compliance Officer and Deputy General Counsel, is promoted to General Counsel and Chief Compliance Officer  (posted on March 5 2026).
• Paula Soteropoulos, Venture Partner, has left the company  (posted on February 24 2026).
• Zoë Rubin has joined the company as Director of Compliance  (posted on February 24 2026).

Click here to view some more movements at 5AM Ventures

Create your alert
to follow the executive moves at 5AM Ventures.

5AM Ventures has 1,642 competitors including Griffin Gaming Partners (United States (USA)), BlackRock (United States (USA)) and KKR (United States (USA)).

Popular M&A news in Fund

• DigitalBridge Group has announced the acquisition of ArcLight Capital Partners  (posted on June 3 2026).
• Prime Capital Financial has acquired Access Capital Partners (posted on June 2 2026).
• Frazier Healthcare Partners has acquired Altruix (posted on May 29 2026).

Popular contacts in Fund

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer at Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director at Vanguard
• Scott Nuttall - Co-Chief Executive Officer and Director at KKR

Learn more about the Fund industry

Press releases by 5AM Ventures

• NodThera Announces Late-Breaking Oral Presentation at the 94th EAS Congress - Nodthera
• Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
• Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
• Entrada Therapeutics | Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
• News – Page 130 – 5AM Ventures
• Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer | Arvinas
• CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation • Tue, 04/28/2026 - 08:00
• Precede Biosciences Launches Precede Bio Insight™, a Genome-Wide Liquid Biopsy for Functional Tumor Biology at AACR 2026 | Precede Biosciences New
• Entrada Therapeutics | Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
• Fellow Health Appoints Industry Executive Paul Kappelman as Independent Chairman of the Board
• View more press releases Close

Social media about 5AM Ventures

• 5AM Ventures on Wikipedia, Google News & Yahoo Finance
• 5AM Ventures on LinkedIn, X (Twitter) & YouTube